Walleye Capital’s Myriad Genetics MYGN Stock Holding History

Walleye Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60K	Buy	+10,500	New	+$47.7K	﹤0.01%	4117
2025 Q4	–	Sell	-6,300	Closed	-$45.5K	–	4944
2025 Q3	$45.5K	Sell	6,300 -19,000	-75%	-$113K	﹤0.01%	4031
2025 Q2	$134K	Buy	+25,300	New	+$149K	﹤0.01%	3619
2024 Q1	–	Sell	-2,000	Closed	-$38.3K	–	5719
2023 Q4	$38.3K	Sell	2,000 -8,200	-80%	-$142K	﹤0.01%	4363
2023 Q3	$164K	Buy	+10,200	New	+$194K	﹤0.01%	3690
2020 Q1	–	Sell	-5,700	Closed	-$155K	–	1413
2019 Q4	$155K	Sell	5,700 -21,800	-79%	-$600K	0.01%	1222
2019 Q3	$787K	Buy	+27,500	New	+$801K	0.05%	546
2019 Q2	–	Sell	-11,200	Closed	-$372K	–	1930
2019 Q1	$372K	Buy	+11,200	New	+$341K	0.06%	504

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Capital's MYGN Position: Q2 2026 in Review

Walleye Capital opened a new position in Myriad Genetics (MYGN) in Q2 2026: 464,647 shares worth $2.65M. The stake represents 0.01% of the portfolio and ranks #1288 among its holdings. This is a return to the name: Walleye Capital previously reported a position in MYGN as recently as Q4 2025.

Walleye Capital first reported a position in MYGN in Q1 2019 and has held it in 18 quarters since. The position peaked at $4.16M in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Walleye Capital held 464,647 shares of Myriad Genetics worth $2.65M as of Q2 2026.
Myriad Genetics was a new Walleye Capital position in Q2 2026.
Myriad Genetics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1288 holding.
Walleye Capital first reported a position in Myriad Genetics in Q1 2019 and has held it in 18 quarters since.
Walleye Capital's Myriad Genetics position peaked at $4.16M in Q4 2025.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.